AnazaoHealth Corporation Initiates Nationwide Class II Recall of Thiamine HCl/Pyridoxine HCl Injection Due to Particulate Matter
AnazaoHealth Corporation initiated a nationwide Class II recall (D-0204-2024) for 3,363 vials of Thiamine HCl/Pyridoxine HCl Injection Solution due to particulate matter. This event, terminated by the FDA, underscores critical quality control failures in sterile compounding. Procurement and regulatory teams must scrutinize injectable suppliers, reinforcing robust qualification processes to mitigate patient safety risks and supply chain disruptions from similar quality lapses.
What the FDA Found: Summary of Quality Control Violations
The FDA's classification of this event as a Class II recall for AnazaoHealth Corporation's Thiamine HCl/Pyridoxine HCl 20 mg/mL /100mg/ml Injection Solution, 30mL Amber Glass Vial (NDC 72682-8721-3) signals a significant quality control failure with potential for adverse health consequences. Initiated voluntarily by AnazaoHealth on November 22, 2023, the recall, identified as D-0204-2024, involved 3,363 vials distributed nationwide across the USA. The core issue was the presence of particulate matter within the injectable solution, a critical concern for any parenteral drug product. This recall impacts multiple lots, specifically 508029, 513191, 524670, 526254, 530738, 533570, 538736, 543220, 543508, and 545675, with expiration dates ranging from December 2023 to February 2024. For procurement directors and supply chain VPs, this event highlights the immediate need to verify the quality assurance protocols of all suppliers providing injectable vitamin formulations. The presence of foreign particles in intravenous products can lead to serious patient harm, including vascular occlusion, phlebitis, and granuloma formation, directly impacting patient safety and potentially leading to significant liability for healthcare providers and distributors. Regulatory affairs heads must ensure that their organizations have robust systems for identifying and isolating affected products, minimizing exposure to such compromised batches.
AnazaoHealth's Operational Footprint and Product Scope
AnazaoHealth Corporation, based at 7465 W Sunset Rd Ste 1200, Las Vegas, NV 89113-1944, operates as a manufacturer within the United States, specializing in drug products. This specific recall pertains to their Thiamine HCl/Pyridoxine HCl 20 mg/mL /100mg/ml Injection Solution, a prescription-only (Rx only) product packaged in 30mL amber glass vials. The nature of this product, a combination vitamin injection, suggests its use in clinical settings for patients requiring parenteral nutritional support or specific vitamin repletion. While the knowledge graph indicates AnazaoHealth as a 'Manufacturer' with a 'low' risk band, the recall of 3,363 vials distributed nationwide underscores the critical importance of stringent quality control at every stage of production, particularly for sterile injectable products. For business development executives, understanding the operational context of such firms is crucial; a recall of this magnitude, even if terminated, can erode trust and necessitate significant investment in remediation and re-establishing market confidence. Procurement teams must recognize that even suppliers with a historically low-risk profile can experience quality excursions, making continuous oversight and facility audits indispensable. The Las Vegas facility's adherence to cGMP standards for sterile compounding is now under direct scrutiny, impacting its reputation and future contracting opportunities within the highly regulated pharmaceutical supply chain.
Supply Chain Implications for Injectable Therapies
The nationwide distribution of AnazaoHealth Corporation's recalled Thiamine HCl/Pyridoxine HCl Injection Solution means that healthcare providers, hospitals, and clinics across the United States were exposed to potentially compromised product. The presence of particulate matter in injectable drugs poses a direct and immediate risk to patient safety, ranging from localized irritation and inflammation at the injection site to more severe systemic reactions like pulmonary emboli, allergic responses, or even infection if the particles are contaminated. For supply chain VPs, this event necessitates an urgent review of all incoming injectable vitamin products, especially those sourced from compounding pharmacies or smaller manufacturers. The 3,363 affected vials represent a significant volume that could have been administered to patients, highlighting the potential for widespread clinical impact and subsequent reputational damage for any entity in the distribution chain. Regulatory affairs heads must ensure that internal protocols for handling recalled products are robust and efficiently executed, including immediate quarantine and return procedures. Furthermore, this incident underscores the need for enhanced due diligence during supplier qualification, focusing specifically on the supplier's environmental controls, aseptic processing capabilities, and final product inspection methods for parenteral drugs. Failure to adequately address these risks can lead to costly product withdrawals, legal liabilities, and, most importantly, compromised patient outcomes.
Sourcing Alternatives for Compounded Injectables
Given the recall of AnazaoHealth Corporation's Thiamine HCl/Pyridoxine HCl Injection Solution, procurement directors must proactively identify and qualify alternative suppliers to prevent future supply disruptions and mitigate patient safety risks. While the ChemLifeIntel Knowledge Graph does not explicitly name alternative suppliers for this specific product, the market for compounded injectable vitamin solutions typically includes a range of specialized compounding pharmacies and pharmaceutical manufacturers. When evaluating new partners, regulatory affairs teams should prioritize firms with a demonstrably strong history of FDA compliance, including recent inspection records free of critical observations related to sterile manufacturing and particulate control. Key qualification criteria should include comprehensive audits of their quality management systems, aseptic processing environments, personnel training, and robust final product release testing. Geographic diversity among suppliers can also enhance supply chain resilience, reducing dependence on a single region or facility. Business development executives exploring new partnerships should consider the lead times required for full qualification, which can range from several months to over a year, depending on the complexity of the product and the stringency of internal validation processes. This recall serves as a critical reminder that relying solely on a supplier's self-declared 'low risk' status is insufficient; independent verification and ongoing monitoring are paramount for maintaining a secure and compliant supply of critical injectable medications.
AnazaoHealth's Compliance Record and Industry Scrutiny
The ChemLifeIntel Knowledge Graph indicates AnazaoHealth Corporation as a 'Manufacturer' with a 'low' risk band, and no prior regulatory actions such as Warning Letters, 483s, or Import Alerts are mentioned in the provided historical intelligence. This current Class II recall (D-0204-2024) for particulate matter in their Thiamine HCl/Pyridoxine HCl Injection Solution therefore represents a significant event that will undoubtedly elevate the company's regulatory risk profile. For regulatory affairs heads, this incident underscores that a clean historical record does not guarantee ongoing compliance, especially in the highly sensitive area of sterile injectable products. The FDA's termination of the recall on September 29, 2025, implies that the agency will monitor AnazaoHealth's corrective actions over an extended period. Procurement directors should interpret this as a signal to intensify their due diligence, even for suppliers previously deemed low-risk. While the specific details of AnazaoHealth's internal investigation and corrective and preventive actions (CAPAs) are not public, the firm is now under increased scrutiny. This event serves as a broader industry reminder that continuous monitoring of supplier quality and regulatory status is non-negotiable, particularly for products with direct patient administration pathways where quality deviations can have immediate and severe consequences.
Remediation Timeline and Future Regulatory Oversight
The FDA's classification of the AnazaoHealth Corporation recall as "Terminated" with a termination date of September 29, 2025, indicates that the agency has concluded its oversight of the firm's recall activities. However, this termination date is notably in the future, suggesting an extended period during which AnazaoHealth is expected to complete all necessary corrective actions and ensure the affected product is no longer in distribution. For regulatory affairs and quality assurance teams, this implies that while the immediate recall action is winding down, the underlying quality system deficiencies that led to the particulate matter issue must be thoroughly addressed. The firm is responsible for investigating the root cause of the particulate matter, implementing robust corrective and preventive actions (CAPAs), and verifying their effectiveness to prevent recurrence. The FDA will likely consider this recall in any future inspections of AnazaoHealth's Las Vegas facility, potentially leading to more rigorous scrutiny of their sterile compounding processes. Business development executives should anticipate that potential partners will now conduct more exhaustive audits of AnazaoHealth's quality systems. This event reinforces the broader industry trend of heightened regulatory expectations for sterile drug manufacturers, where even a single quality lapse can trigger extensive recalls, significant financial costs, and lasting damage to a company's reputation and market access.